MOLECULAR ANALYSIS OF THE 5Q--CHROMOSOME

被引：29

作者：

NAGARAJAN, L

机构：

[1] Department of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 17卷 / 5-6期

关键词：

CHROMOSOME; 5Q31; REFRACTORY ANEMIA; MYELODYSPLASIA; TUMOR SUPPRESSOR LOCI;

D O I：

10.3109/10428199509056846

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acquired interstitial deletions of the long arm of chromosome 5, are seen in anomalies of the myeloid cells. The refractory anemia (RA) or 5q- syndrome, in which the erythroid and megakaryocytic lineages are predominantly affected, is a relatively indolent clinical entity distinguishable, from the constellation of preneoplastic myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) with trilineage involvement. Recent molecular evidence suggests that the critical region of 5q deletion in MDS/AML resides in the D5S89 locus, which is proximal (centromeric) to the minimal region of loss in the 5q- syndrome RA. The invariable loss of the D5S89 locus in MDS/AML qualifies it for the MDS/AML tumor suppressor locus. The telomeric 5q31 gene governs erythroid and megakaryocytic differentiation and can be termed the RA locus. Isolation and characterization of these genes will lead to an understanding of molecular mechanisms underlying normal hematopoiesis and leukemic transformation.

引用

页码：361 / 366

页数：6

共 38 条

[1]

Van den Berghe H., Cassiman J.J., David G., Fryns J.P., Sokal G., Distinct haematological disorder with deletion of long arm of No. 5 chromosome, Nature, 251, pp. 437-438, (1974)

[2]

Soakl G., Michaux J.L., Van den Berghe H., Cordier A., Rodhein J., Ferrant A., Moriau M., De Bruyere M., Sonnet J., A new hematologic syndrome with a distinct karyotype: the 5q-chromosome, Blood, 45, pp. 519-533, (1975)

[3]

Kerkhofs H., Hagemeier C.H., Leeksma C.H.W., Abels J., Den Ottolander G.J., Somers R., Gerrits W.B.J., Langenhuiyen M.M.A.C., Von dem Borne A.E.G.K., Van Hemel J.O., Geraedts J.P.M., The 5q-chromosome abnormality in hematological disorders, Brit. J. Haemotol, 52, pp. 365-381, (1982)

[4]

Dewald G.W., Davis M.P., Pierre R.V., O'Fallon J.R., Hoagland H.C., Clinical characteristics and progress of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5, Blood, 66, pp. 189-197, (1985)

[5]

Le Beau M.M., Albain K.S., Larson R.A., Vardiman J.W., Davis E.M., Blough R.R., Golomb H.M., Rowley J.D., Clinical and cytogenetic correlations in 63 patients with therapy related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes No. 5 and 7, J. Clin. Oncol., 4, pp. 325-345, (1986)

[6]

Van den Berghe H., Vermaelen K., Mecucci C., Barbieri D., Tricot G., The 5q-anomaly, Cancer Genet. Cytogenet., 17, pp. 189-255, (1985)

[7]

Nimer S.D., Golde D.W., The 5q-abnormality, Blood., 70, pp. 1705-1712, (1987)

[8]

Knudson A.G., Retinoblastoma: a prototypic hereditary neoplasm, Semin. Oncol., 5, pp. 57-60, (1978)

[9]

Estey E.H., Keating M.J., Dixon D.O., Trujillo J.M., McCredie K.B., Freireich E.J., Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia, Hematol. Path., 1, pp. 203-208, (1987)

[10]

Keating M.J., Cork A., Broach Y., Smith T., Walters R.S., McCredie K.B., Trujillo J., Freireich E.J., Towards a clinically relevant cytogenetic classification of acute myelogenous leukemia, Leukemia Res., 11, pp. 119-133, (1987)

← 1 2 3 4 →